{Reference Type}: Journal Article
{Title}: Bleeding Risk in Hemodialysis Patients.
{Author}: van Eck van der Sluijs A;Pai P;Zhu W;Ocak G;
{Journal}: Semin Nephrol
{Volume}: 43
{Issue}: 6
{Year}: 2023 Nov 17
{Factor}: 4.472
{DOI}: 10.1016/j.semnephrol.2023.151478
{Abstract}: Cardiovascular diseases are highly prevalent among patients on dialysis. For these diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K antagonists, and direct oral anticoagulants, are being used. However, the benefit-risk balance of these therapies could differ for dialysis patients compared with the general population. This review article focuses on the bleeding risk associated with the use of heparin, antiplatelets, vitamin K antagonists, and direct oral anticoagulants in patients receiving hemodialysis.